/Patent Tracker
GooglePatent applicationHealth & bodyInterest 7/10

Google's Verily unit patents blood test to predict severe COVID-19 cases

This patent describes a method for analyzing specific blood cells to identify people at high risk of developing severe symptoms from SARS-CoV viruses. It looks for changes in gene activity and cell structure in monocytes and T cells to create a risk profile.

Why it mattersDoctors could use this blood test to spot which patients need immediate intensive care, helping hospitals manage resources better during outbreaks.

In the filing’s own words

A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.

What exactly they claim (claim 1)

1. A method for determining a signature for identifying a subject at risk of a severe reaction to a SARS-CoV virus comprising: (i) obtaining a blood sample from a subject who has tested positive for the SARS-CoV virus; (ii) identifying a cell from the blood sample of the subject, wherein the cell is an intermediate monocyte (Moln), non-classical monocyte (MoNC), classical monocyte (MoCl), and/or CD8+ effector memory T cell; and (iii) performing an assay on the cell to detect a feature comprising: (a) a first differentially expressed gene (DEG) in the Moln, MoNC, or MoCl (b) a second DEG in the CD8+ effector memory T cell, and/or (c) elevated chromatin accessibility in the Moln; wherein the signature comprises the feature.

Facts

Company
Google (Verily Life Sciences LLC)
Official title
MULTI-OMIC PROFILING SIGNATURES FOR COVID-19
Publication number
US20260265825A1
Application number
19167290
Filed
Apr 18, 2024
Published
Sep 10, 2026
Inventors
7
Claims
26

Classified under

C12Q 1/6883 Chemistry & metalsG01N 33/6893 Physics & computingC12Q 2600/118 Chemistry & metalsC12Q 2600/158 Chemistry & metalsG01N 2333/165 Physics & computingG01N 2800/50 Physics & computing
Read the full filing (official PDF) ↗ Open in the Patent Tracker

More from Google in Health & body

Summaries are simplified from the filing’s own abstract and first claim. A patent filing is not a product announcement.
Patent data and drawings: U.S. Patent and Trademark Office (USPTO). Nebula is not affiliated with or endorsed by the USPTO.